ethyl 4-(2-methyl-1,3-dioxolan-2-yl)benzoate | 219836-34-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ethyl 4-(2-methyl-1,3-dioxolan-2-yl)benzoate
• 英文别名: 1-[4-(ethoxycarbonyl)phenyl]ethanoneethyleneacetal；1-[4-(Ethoxycarbonyl)phenyl]ethanone-ethyleneacetal
• CAS: 219836-34-7
• 化学式: C₁₃H₁₆O₄
• 分子量: 236.268
• InChiKey: YTDSIPMQJPDTGM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  44.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  4-乙酰基苯甲酸乙酯 在 对甲苯磺酸一水合物 作用下， 以 乙二醇 、 甲苯 为溶剂， 生成 ethyl 4-(2-methyl-1,3-dioxolan-2-yl)benzoate
  参考文献：
  名称：

  US6037362

  摘要：

  公开号：

文献信息

• Novel tricyclic compounds and drug compositions containing same
  申请人：ASAHI KASEI KOGYO KABUSHIKI KAISHA

  公开号：US20030139475A1

  公开（公告）日：2003-07-24

  Compounds having a &bgr;-3 adrenaline receptor agonist and are useful as drugs for the treatment and prevention of diabetes, obesity, hyperlipemia, etc., represented by a general formula (I) and salts thereof, and a process for producing these, and their intermediates, wherein R represents hydrogen or methyl; R 1 represents hydrogen, halogen, hydroxy, benzyloxy, amino, or hydroxymethyl; R 2 represents hydrogen, hydroxymethyl, NHR 3 , SO 2 NR 4 R 4′ , or nitro; R 6 represents hydrogen or lower alkyl; and X represents nitrogen, R 9 represents hydrogen, one of R 7 and R 8 represent hydrogen, and the other thereof represents hydrogen, amino, acetylamino, or hydroxy.

  具有&bgr;-3肾上腺素受体激动剂的化合物，可用于治疗和预防糖尿病、肥胖症、高脂血症等疾病，其通式表示为(I)，并且包括其盐，以及制备这些化合物和其中间体的方法。其中，R代表氢或甲基；R1代表氢、卤素、羟基、苄氧基、氨基或羟甲基；R2代表氢、羟甲基、NHR3、SO2NR4R4′或硝基；R6代表氢或低碳基；X代表氮；R9代表氢；R7和R8中的一个代表氢，而另一个代表氢、氨基、乙酰氨基或羟基。
• Tricyclic compounds and drug compositions containing same
  申请人：Asahi Kasei Kogyo Kabushiki Kaisha

  公开号：US06545053B1

  公开（公告）日：2003-04-08

  Compounds having a &bgr;-3 adrenaline receptor agonist and are useful as drugs for the treatment and prevention of diabetes, obesity, hyperlipemia, etc., represented by a general formula (I) and salts thereof, and a process for producing these, and their intermediates, wherein R represents hydrogen or methyl; R1 represents hydrogen, halogen, hydroxy, benzyloxy, amino, or hydroxymethyl; R2 represents hydrogen, hydroxymethyl, NHR3, SO2NR4R4′, or nitro; R6 represents hydrogen or lower alkyl; and X represents methylene, R9 represents hydrogen, one of R7 and R8 represent hydrogen, and the other thereof represents hydrogen, amino, acetylamino, or hydroxy.

  具有&bgr;-3肾上腺素受体激动剂的化合物，可用作治疗和预防糖尿病、肥胖症、高脂血症等药物，其通式表示为（I），和其盐，以及制备这些化合物和其中间体的方法，其中R代表氢或甲基；R1代表氢，卤素，羟基，苄氧基，氨基或羟甲基；R2代表氢，羟甲基，NHR3，SO2NR4R4'或硝基；R6代表氢或较低烷基；X代表亚甲基，R9代表氢，R7和R8中的一个代表氢，另一个代表氢，氨基，乙酰氨基或羟基。
• NOVEL TRICYCLIC COMPOUNDS AND DRUG COMPOSITIONS CONTAINING THE SAME
  申请人：Asahi Kasei Kogyo Kabushiki Kaisha

  公开号：EP0882707A1

  公开（公告）日：1998-12-09

  Compounds represented by general formula (I) or salts thereof, a process for producing the same, and intermediates therefor, wherein R represents hydrogen or methyl; R1 represents hydrogen, hologeno, hydroxy, benzyloxy, amino, or hydroxymethyl; R2 represents hydrogen, hydroxymethyl, NHR3, SO2NR4R4, or nitro; R6 represents hydrogen or lower alkyl; and X represents nitrogen, oxygen, sulfur, or methylene, provided that when X represents nitrogen, oxygen, or sulfur, then R9 represents hydrogen, one of R7 an R8 represents hydrogen, and the other thereof represents hydrogen, amino, acetylamino, or hydroxy, and when X represents methylene, then R7 and R8 each represents hydrogen and R9 represents hydrogen, amino, etc. They have a β-3 adrenaline receptor agonist and are useful as drugs for the treatment and prevention of diabetes, obesity, hyperlipemia, etc.

  通式(I)所代表的化合物或其盐类，以及生产该化合物或其盐类的工艺和中间体，其中R代表氢或甲基；R1代表氢、囟素、羟基、苄氧基、氨基或羟甲基；R2代表氢、羟甲基、NHR3、SO2NR4R4或硝基；R6代表氢或低级烷基；X代表氮、氧、硫或亚甲基，但当X代表氮、氧或硫时，R9代表氢，R7和R8中的一个代表氢，另一个代表氢、氨基、乙酰氨基或羟基；当X代表亚甲基时，R7和R8各自代表氢，R9代表氢、氨基等。它们具有β-3肾上腺素受体激动剂的作用，可作为治疗和预防糖尿病、肥胖症、高脂血症等的药物。
• NOVEL TRICYCLIC COMPOUNDS HAVING SATURATED RINGS AND MEDICINAL COMPOSITIONS CONTAINING THE SAME
  申请人：Asahi Kasei Kogyo Kabushiki Kaisha

  公开号：EP0997458A1

  公开（公告）日：2000-05-03

  Compounds represented by general formula (I) or their salts, having β3 -adrenoceptor agonism and being efficacious when employed in drugs for treating and preventing diabetes, obesity, hyperlipemia, etc. wherein R represents hydrogen or methyl; R1 represents hydrogen, halogeno, hydroxy, benzyloxy, amino or hydroxymethyl; R2 represents hydrogen, hydroxymethyl, NHR3, SO2NR4R4', or nitro (wherein R3 represents hydrogen, methyl, SO2R5, formyl or CONHR6'; R5 represents lower alkyl, benzyl or NR4R4'; R4 and R4' may be the same or different and each represents hydrogen, lower alkyl or benzyl; and R6' represents hydrogen or lower alkyl); R6 represents hydrogen or lower alkyl; n is 1 or 2; X represents secondary nitrogen, oxygen or sulfur; and when n is 1, then one of R7 and R8 represents hydrogen while another represents hydrogen, amino, acetylamino or hydroxy, or when n is 2, then R8 represents hydrogen while R7 represents hydrogen, amino, acetylamino or hydroxy.

  通式(I)所代表的化合物或其盐类，具有 β3-肾上腺素受体激动作用，在用于治疗和预防糖尿病、肥胖症、高血脂症等药物时具有疗效。其中 R 代表氢或甲基；R1 代表氢、卤素、羟基、苄氧基、氨基或羟甲基；R2 代表氢、羟甲基、NHR3、SO2NR4R4'或硝基（其中 R3 代表氢、甲基、SO2R5、甲酰基或 CONHR6'；R5 代表低级烷基、苄基或 NR4R4'；R4 和 R4'可以相同或不同，各自代表氢、低级烷基或苄基；和 R6' 代表氢或低级烷基）；R6 代表氢或低级烷基；n 为 1 或 2；X 代表仲氮、氧或硫；当 n 为 1 时，则 R7 和 R8 中的一个代表氢，而另一个代表氢、氨基、乙酰氨基或羟基，或当 n 为 2 时，则 R8 代表氢，而 R7 代表氢、氨基、乙酰氨基或羟基。
• MSTFA as an Effective TMS Source for the TMSOTf-Catalzyed Synthesis of Cyclic Acetals
  作者：Suttipol Radomkit、Jada A. H. White、Eugene Chong、Yongda Zhang

  DOI：10.1021/acs.joc.4c00020

  日期：2024.4.19

  lsilyl)acetamide] was identified as a highly effective TMS (trimethylsilyl) source for the convenient preparation of cyclic acetals under modified Noyori’s conditions. The reactions proceeded smoothly under mild conditions, affording a wide range of the corresponding cyclic acetals with excellent yields in the presence of catalytic TMSOTf (trimethylsilyl trifluoromethanesulfonate). The present method

  市售且容易获得的 MSTFA [2,2,2-三氟-N-甲基-N- (三甲基甲硅烷基)乙酰胺]被认为是一种高效的 TMS（三甲基甲硅烷基）来源，可在改进的 Noyori 条件下方便地制备环状缩醛。反应在温和条件下顺利进行，在催化 TMSOTf（三氟甲磺酸三甲基硅酯）存在下以优异的产率生成了各种相应的环状缩醛。本方法不需要大量过量的有价值的二醇，并且不需要预先合成的甲硅烷基化二醇。与其他甲硅烷基化试剂如BSA [ N , O-双(三甲基硅基)乙酰胺]和BSTFA[ N , O-双(三甲基硅基)三氟乙酰胺]相比，MSTFA的应用避免了副产物2对催化缩醛化的抑制， 2,2-三氟-N-甲基乙酰胺。